CD8A and neoplasm: demonstrated that multiple cycles of IP-delivered patient-derived type I CD4+ T helper cells (Th1) with cytokines IL-2 and IFNγ, enhanced the anti-tumor activity of autologous CD8+ T cells against the tumor-specific glycoform of MUC1 in ovarian cancer patients [75,78].